The mid-market private equity firm continues its run of investments in the pharma services segment with a stake in the London-based life sciences consultancy.
Baird Capital, a US and UK based mid-market private equity firm, has taken a stake in Newmarket Strategy, a London-based life sciences consultancy and market access specialist.
The investment was made via Baird Capital’s Global Private Equity Fund. Financial details have not been disclosed.
Founded in 2021, Newmarket works with clients to assess market opportunities, secure reimbursement from national and local payors, and drive the uptake of health innovations. The firm is recognised for its expertise across the bench-to-bedside value chain. Clients include global pharmaceuticals and biotech, med-tech, diagnostics, digital health, private equity and healthcare services providers. It also has key strengths in policy and government affairs.
The investment will support the company’s continued growth.
Michael Holgate, partner with Baird Capital’s Global Private Equity team said that the investment follows a number of previous investments that the fund has made in the pharma services segment in recent years including Campbell Alliance, Prescient and Blue Matter – all consulting firms focused on the pharmaceutical and life sciences industry.
Baird Capital was advised by Squire Patton Boggs (legal), Clearwater (corporate finance), T4 (voice of customer), Candesic (commercial diligence), BDO (financial and tax), New Street Consulting (management), and WTW (insurance) while Newmarket was advised by JMW (legal) and MHA (corporate advisory).
